EZH2 and neoplasm: Studies have shown that combining HMT inhibitors, such as EZH2 inhibitors, with immunotherapy, targeted therapy, chemotherapy, and endocrine therapy can result in synergistic anti-tumor effects, improving treatment outcomes.